Surrozen, Inc./DE Research and Development Expense
Surrozen, Inc./DE (SRZN) reported Research and Development Expense of $8.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Surrozen, Inc./DE research and development expense for the quarter ending 2026-06-30 was $8.48M, a 40.42% increase year-over-year.
- Surrozen, Inc./DE research and development expense for the quarter ending 2026-03-31 was $9.33M, a 42.24% increase year-over-year.
- Surrozen, Inc./DE research and development expense for the quarter ending 2025-12-31 was $8.99M, a 68.06% increase year-over-year.
- Surrozen, Inc./DE research and development expense for the quarter ending 2025-09-30 was $7.77M, a 49.50% increase year-over-year.
- Surrozen, Inc./DE research and development expense for fiscal 2025 was $29.36M, a 38.96% increase from fiscal 2024.
- Surrozen, Inc./DE research and development expense for fiscal 2024 was $21.13M, a 22.39% decline from fiscal 2023.
- Surrozen, Inc./DE research and development expense for fiscal 2023 was $27.23M, a 26.43% decline from fiscal 2022.
- Surrozen, Inc./DE research and development expense for fiscal 2022 was $37.01M, a 7.88% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.48M 10-Q · filed 2026-08-06 | $17.81M 10-Q · filed 2026-08-06 | $26.80M derived: sum of 3 quarters · filed 2026-08-06 | $34.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.33M 10-Q · filed 2026-05-06 | $18.32M derived: sum of 2 quarters · filed 2026-05-06 | $26.09M derived: sum of 3 quarters · filed 2026-05-06 | $32.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $16.77M derived: sum of 2 quarters · filed 2026-03-23 | $22.81M derived: sum of 3 quarters · filed 2026-08-06 | $29.36M 10-K · filed 2026-03-23 |
| 2025-09-30 | $7.77M 10-Q · filed 2025-11-07 | $13.82M derived: sum of 2 quarters · filed 2026-08-06 | $20.37M 10-Q · filed 2025-11-07 | $25.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.04M 10-Q · filed 2026-08-06 | $12.60M 10-Q · filed 2026-08-06 | $17.95M derived: sum of 3 quarters · filed 2026-08-06 | $23.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.56M 10-Q · filed 2026-05-06 | $11.91M derived: sum of 2 quarters · filed 2026-05-06 | $17.11M derived: sum of 3 quarters · filed 2026-05-06 | $22.44M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $10.55M derived: sum of 2 quarters · filed 2026-03-23 | $15.88M derived: sum of 3 quarters · filed 2026-03-23 | $21.13M 10-K · filed 2026-03-23 |
| 2024-09-30 | $5.20M 10-Q · filed 2025-11-07 | $10.54M derived: sum of 2 quarters · filed 2025-11-07 | $15.78M 10-Q · filed 2025-11-07 | $21.88M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $5.33M 10-Q · filed 2025-08-08 | $10.58M 10-Q · filed 2025-08-08 | $16.68M derived: sum of 3 quarters · filed 2025-08-08 | $22.79M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $5.25M 10-Q · filed 2025-05-09 | $11.34M derived: sum of 2 quarters · filed 2025-05-09 | $17.45M derived: sum of 3 quarters · filed 2025-05-09 | $24.39M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $12.21M derived: sum of 2 quarters · filed 2025-03-31 | $19.14M derived: sum of 3 quarters · filed 2025-03-31 | $27.23M 10-K · filed 2025-03-31 |
| 2023-09-30 | $6.11M 10-Q · filed 2024-11-06 | $13.05M derived: sum of 2 quarters · filed 2024-11-06 | $21.14M 10-Q · filed 2024-11-06 | $30.57M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $6.94M 10-Q · filed 2024-08-12 | $15.02M 10-Q · filed 2024-08-12 | $24.46M derived: sum of 3 quarters · filed 2024-08-12 | $33.08M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $8.09M 10-Q · filed 2024-05-08 | $17.52M derived: sum of 2 quarters · filed 2024-05-08 | $26.15M derived: sum of 3 quarters · filed 2024-05-08 | $35.73M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $18.06M derived: sum of 2 quarters · filed 2024-04-10 | $27.64M derived: sum of 3 quarters · filed 2024-04-10 | $37.01M 10-K · filed 2024-04-10 |
| 2022-09-30 | $8.62M 10-Q · filed 2023-11-08 | $18.20M derived: sum of 2 quarters · filed 2023-11-08 | $27.58M 10-Q · filed 2023-11-08 | $38.47M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $9.58M 10-Q · filed 2023-08-09 | $18.95M 10-Q · filed 2023-08-09 | $29.84M derived: sum of 3 quarters · filed 2023-08-09 | $40.26M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $9.37M 10-Q · filed 2023-05-10 | $20.26M derived: sum of 2 quarters · filed 2023-05-10 | $30.68M derived: sum of 3 quarters · filed 2023-05-10 | $40.95M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $21.31M derived: sum of 2 quarters · filed 2023-03-31 | $31.58M derived: sum of 3 quarters · filed 2023-03-31 | $40.18M 10-K · filed 2023-03-31 |
| 2021-09-30 | $10.42M 10-Q · filed 2022-11-14 | $20.68M derived: sum of 2 quarters · filed 2022-11-14 | $29.28M 10-Q · filed 2022-11-14 | $37.93M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.27M 10-Q · filed 2022-08-11 | $18.87M 10-Q · filed 2022-08-11 | $27.52M derived: sum of 3 quarters · filed 2022-08-11 | $34.47M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $8.60M 10-Q · filed 2022-05-11 | $17.25M derived: sum of 2 quarters · filed 2022-05-11 | $24.21M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $15.61M derived: sum of 2 quarters · filed 2022-03-28 | $25.68M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $6.96M 10-Q · filed 2021-11-15 | $17.03M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |